Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.

Summary

The aim of this study is to confirm the safety and pharmacological characteristics of SAP-001, evaluate its efficacy in lowering sUA and tophus burden, and identify the appropriate dose regimen for future studies in adult subjects with gout, with or without tophi, and hyperuricemia refractory to SoC XOI therapy.

Timeline

Start

2022-12-12

Primary completion

2025-01

Completion

2025-02

Drugs

Indications